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Abstract 
Background: Many genome-wide association studies have detected genomic regions associated with traits, yet 
understanding the functional causes of association often remains elusive. Utilizing systems approaches and 
focusing on intermediate molecular phenotypes might facilitate biologic understanding.  
Results: The availability of exome sequencing of two populations of African-Americans and European-Americans 
from the Atherosclerosis Risk in Communities study allowed us to investigate the effects of annotated loss-of-
function (LoF) mutations on 122 serum metabolites. To assess the findings, we built metabolomic causal networks 
for each population separately and utilized structural equation modeling. We then validated our findings with a 
set of independent samples. By use of methods based on concepts of Mendelian randomization of genetic variants, 
we showed that some of the affected metabolites are risk predictors in the causal pathway of disease. For example, 
LoF mutations in the gene KIAA1755 were identified to elevate the levels of eicosapentaenoate (p-value=5E-14), 
an essential fatty acid clinically identified to increase essential hypertension. We showed that this gene is in the 
pathway to triglycerides, where both triglycerides and essential hypertension are risk factors of metabolomic 
disorder and heart attack. We also identified that the gene CLDN17, harboring loss-of-function mutations, had 
pleiotropic actions on metabolites from amino acid and lipid pathways. 
Conclusion: Using systems biology approaches for the analysis of metabolomics and genetic data, we integrated 
several biological processes, which lead to findings that may functionally connect genetic variants with complex 
diseases. 
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Background 
Lack of knowledge of underlying biological processes in genome wide association studies and disease endpoints 
has led to a focus on intermediate phenotypes, such as metabolites. Metabolomic profiles are integrated readouts 
of many biological processes and can functionally connect genetic variants to disease risk factors and complex 
disease endpoints (1)(2)(3). Furthermore, metabolomics can be used to screen for early disease-related changes 
(4) and assess effects of external stimuli on living cells (5). Considering metabolites as an intermediate molecular 
mediator between genes and clinical endpoints offers potential to illuminate mechanisms underlying a specific 
single nucleotide polymorphism (SNP)/gene, as well strengthen the association of a gene with the intermediate 
trait (6)(7). Thus, metabolite profiles are ideal intermediate biochemical phenotypes for genome wide association 
studies (GWAS) (6)(8)(9)(10) and whole genome sequencing studies (11)(12).  
Examining metabolomic relationships facilitates understanding of functional links between genetic variants and 
disease endpoints, which goes beyond traditional association analyses that examine one variable at a time. 
Analyses that consider the joint effects of multiple traits can have greater statistical power than single-trait 
analyses of genomic association studies (13)(14)(15). In addition, assigning probabilistic models to expression 
levels of a group of genes (usually within one pathway) enables development of more accurate classifiers and 
clusters (16)(17)(18)(19). For high-dimensional metabolomic data, systems approaches based on Mendelian 
randomization principles can provide an even more comprehensive analysis. To advance a deeper understanding 
of how genes and metabolites might be interconnected, Yazdani et al. (2016) introduced and applied systems 
biology approaches that can reveal the underlying relationships and provide insights in metabolomics system 
(20)(21). We capitalize on this prior work and introduce an approach to improve genome analysis and assess 
pleiotropic gene actions.  
We investigated the effects of genetic variants on the human metabolome in the populations of white and non-
white from the Atherosclerosis Risk in Communities (ARIC) study (22). In particular, we focus on loss-of-
function (LoF) variants that are predicted to result in a non-viable transcript or a greatly truncated protein product 
(23). To analyze the LoF-metabolite relationships, we utilized two approaches: 1) a single variant test, and 2)  a 
convex-concave rare variant selection (CCRS) approach (11)(24). This latter approach selects genetic variants 
through a penalization linear model, which assumes sparsity in genomic associations while considering the local 
linkage disequilibrium. We then applied a systems approach called Genome Directed Acyclic Graph (G-DAG) 
(25) to model the metabolomic relationships in causal networks. This G-DAG method assured that the necessary 
assumptions were met in order to then use structural equation modeling to assess genetic findings. This integrative 
approach facilitates a mechanistic understanding of how genes and metabolites are related by incorporating and 
modeling relationships of a large number of metabolites and genetic variants, improves genome-metabolite 
pathway identification, and identifies genes with multiple functions (i.e. pleiotropic actions). Some of the 
metabolomic causal pathways identified using the G-DAG algorithm matched the available 
knowledge (20)(21) and some of the novel findings of the G-DAG algorithm are validated clinically (26).  
Results  
To investigate the association of LoF genetic variants with metabolites, we used linear regression to first adjust 
all metabolites for the covariates age, gender, body mass index, phase (two different time points that the 
metabolites were measured), and ten principal components (to adjust for population stratification). We then 
identified mutations in the coding sequence (individually or in aggregate within a gene) with significant effect on 
metabolites. To achieve this, we used two methods to select strong associations. One approach is a penalized 
model based on gene-level analyses (simultaneously evaluating all LoF variants in a gene), and is called the CCRS 
method (Convex-Concave Rare variant Selection). The CCRS method uses a tuning parameter to select LoF-
metabolite associations. The set of tuning parameters included 1.5, 0.3 and 0.01, and the tuning parameter that 
resulted in the minimum BIC was chosen in the final model. The findings are provided in tables S4 and S5 for EA 
and AA respectively. The second approach was based on single variant tests, and the level of statistical 
significance for the test was based on Bonferroni correction for 122 metabolites, 451 and 372 LoF mutations in 
EA (European-American/white) and AA (African-American/non-white) populations respectively. The findings 
are provided in tables S6 and S7 for EA and AA respectively. We then focused on the variants that were commonly 
selected by both approaches to reduce the false discovery rate.  
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The EA and AA participants differed in several ways. The size of covariate effects differed between the EA and 
AA subjects, the EA and AA individuals were from different geographical regions, and different diets and 
environment could impact biochemical pathways. Furthermore, ancestry can affect metabolites. In an attempt to 
reduce confounders, including environmental and regional dietary variations that may impact metabolites, we 
focused on AA participants from Jackson, Mississippi. We identified the underlying metabolomic relationships 
separately for the EA and AA groups and we did not expect that the two causal networks EA and AA be identical. 
However, the two causal networks were very similar with respect to the metabolites with essential roles in the 
metabolomic system. For example, the relationship between leucine, valine, and isoleucine and the high impact 
of these three metabolites in the metabolomic system were the same in both causal networks. Among fatty acids, 
however, the relationships between AA and EA were not very similar. Because differences between EA and AA 
participants might make it impossible to compare the results between these two populations, we avoided any 
comparison below.   
We integrated the results of LoF-metabolite investigation with the identified metabolomic causal network in each 
population. To identify underlying relationships among metabolites, we utilized the G-DAG algorithm and 
identified a metabolomic causal network over 122 metabolites distributed across multiple functional classes in 
each population. Because the principles of the G-DAG algorithm are based on Mendelian randomization, where 
genetic variants act as instrumental variables, hence anchoring the direction of causation, the results from this 
algorithm provide directions of effects in a network. This provided a valid way to subsequently use structural 
equation modeling, see the method section and (27). Figure 1 illustrates the steps of the analysis. The findings are 
presented in Tables 1 and 2 for EA and AA, respectively and some of them are validated using an independent 
sample.  
 
Genome Analysis of AA Population 
Some of the results from our genome analysis of the AA population are illustrated and described below.  
GPR97: In the genome analysis, GPR97 showed significant effects on the metabolites glycocholenate-sulfate, 
oleate, and eicoseneate from the lipid pathway; therefore, this gene was hypothesized to have pleiotropic action. 
Looking at the relationships among the metabolites (Figure 2), we observed the metabolites oleate and eicoseneate 
to have direct relationshisps. Using structural equation models to estimate the effect of GPR97 on eicoseneat, we 
found this effect to not be statistically significant. Therefore, we concluded that GPR97 does not have a pleiotropic 
action on both metabolites oleate and eicoseneate, but rather GPR97 directly influences only the oleate metabolite. 
 
BNIPL: From the genome analysis, we found that BNIPL has significant effects on the two metabolites 
octanoylcarnitine and decanoylcarnitine from the lipid pathway (sub-pathway carnitine metabolism). Therefore, 
we hypothesized that BNIPL has a pleiotropic effect. From the metabolomic causal network, we found that the 
two metabolites are directly associated (Figure 3). To assess the hypothesized pleiotropic effect of BNIPL, we 
modeled the relationship between the two metabolites using structural equation models. The results from this 
analysis showed that effect of BNIPL on octanoylcarnitine did not remain statistically significant. Therefore, the 
pleiotropic hypothesis was rejected.  
Note that Figures 2 and 3 both are showing the same causal network. In Figure 2, we focused on the metabolites 
affected by GPR97 and in Figure 3, we focused on the metabolites affected by BNIPL. In each Figure, we 
highlighted the relationship between the metabolites of interest and brought those metabolites to the border of the 
causal network to show the relationships. 
The impact of LoF mutations on AA and EA metabolomics 
Further analyses of the metabolomic causal network identified five modules (densely connected metabolites). We 
noticed that the identified modules each referred to a set of metabolites with similar function (e.g. metabolites in 
a pathway) that work together to achieve a coordinated biologic outcome. Below we summarize the effect of LoF 
mutations on the identified modules.  
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One of the modules includes hippurate, p-cresol sulfate, methylcatecholsulfate, catecholsulfate, and 
phenylacetylglutamine, with urea and glutarylcarnitine as neighbors. Investigation of these metabolites indicates 
that they mostly result from gut metabolism of a diet rich in protein and polyphenols. Many of these metabolites 
represent major gut contributions to uremic solutes (e.g. methylcatechol sulfate) and uremic toxicity (e.g. p-cresol 
sulfate) (28)(21). In the AA causal network, the LoF-metabolite findings revealed that these metabolites were 
highly influenced by genes harboring LoF mutations: phenylacetylglutamine is influenced by DCLK3 (p=4e-09), 
ZSWIM1 (p=4e-15), and TMPRSS3 (p=2e-16); urea is influenced by LTK (p=6e-09), AVEN (p=2e-08) and CLSPN 
(p=1e-13), and glutarylcarnitine is influenced by GUCA1C (p=4e-11) (seeFigure 4). In contrast, these metabolites 
were not influenced by any LoF loci in the EA causal network. 
In the AA causal network, hormone-related metabolites were significantly influenced by LoF mutations (Figure 
5). These hormone-related metabolites did not influence other metabolites in the metabolomic causal network. 
Therefore, the LoF loci associated with hormone-related metabolites did not influence other metabolites in the 
metabolomic causal network.  
 
In the EA causal network, the hormone-related metabolites glycocholenate sulfate, pregn steroid monosulfate, and 
androsten-3-beta-17-beta-diol-disulfate 1 were influenced by LTK (p=6e-09), DSE (p=1e-07), and PLAC4 (p=4e-
09,) respectively.  
 
For the diet-related metabolites heptanoate, adipate, azelate, sebacate, dodecanedioate, and glutarate, the gene 
CAPN9 (p=1e-7) influenced heptanoate in the AA population. In the EA causal network, the gene, MYO1A, 
influenced (p=4e-09) heptanoate and the gene PDE4DIP  influenced dodecanedioate (p=1e-14). Among 16 long 
chain fatty acids in the analysis, oleate and nonadecanoate, were affected by LoF loci in the AA causal network. 
Oleate was affected by two genes, GPR97 (p=4e-07) and MAP10 (p=4e-9), and the nonadecanoate was affected 
by CLEC4C (p=4e-10). In the EA causal network, long chain fatty acid myristoleate was affected by two genes, 
ZNF211 (p=1e-9) and EGFL8 (p=8e-13).  
In the module including amino acid related metabolites in the AA causal network, two peptides from the gamma-
glutamyl sub-pathway were influenced by LoF loci: leucine by OR11G2 (p=5e-10) and CYP2A6 (p=1e-11), and 
glutamate by COASY (p=4e-09) and STPG1 (p=1e-12). In the EA population, no LoF mutation had any impact on 
metabolites from the amino acid module.  
Findings in EA and AA populations based on metabolite pathways: In AA, 34 metabolites were significantly 
affected by LoF loci; in EA, 19 metabolites. A summary of the pathway-based metabolites is provided in Table 
3.  
Table 3. Number of pathway-based metabolites influenced by LoF loci. 
Pathway AA EA 
Lipid 11 13 
Amino 
Acid  
15 3 
Peptide 5 1 
others 3 3 
Figure 6 shows the minor allele frequency (MAF%) for LoF loci and the selected LoF loci in each of the 
populations. This figure does not show any differences in MAF% between AA and EA populations.  
 
To validate the findings, we used a validation set from the same AA population including 672 samples with 154 
LoF carriers with MAF>7. In the replication analysis, 8 of the gene-metabolite findings were replicated (p <2.6E-
06), depicted with an asterisk in Table 2.  
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Discussion  
To make fully informed inference about the likely function of genomic variants, systems biology approaches that 
help to understand the pathway of the genetic effects on disease through intermediate molecular levels offer 
improvements over standard single-variable analyses commonly used in GWAS. We investigated the effects of 
LoF genomic variants on the human metabolome in the two ethnic groups of EA and AA participants from the 
ARIC study. To investigate LoF-metabolite relationships, we selected genetic variants that were found to be 
statistically associated with metabolites by both a penalized model (CCRS) and single variant tests. We identified 
metabolomic causal networks using the G-DAG algorithm that is based on a systems biology method. This 
allowed us to integrate genomic and metabolomic relationships, built on directed acyclic graphs that portray 
directions, thus meeting the assumptions of the structural equation modeling that we used to assess the LoF-
metabolite findings. Because differences between EA and AA participants, such as the size of covariate effects, 
different geographical regions and as a result different diet, could impact biochemical pathways, we avoided any 
comparisons of EA and AA metabolomic causal networks in this study.  
Although many of our findings were for rare genetic variants, which made it difficult to corroborate our results 
from published reports, we were able to find published reports that supported some of our results. We identified 
some LoF mutations with high impact on fatty acid metabolism that may play a role in the pathogenesis of 
metabolic syndrome and cardiovascular disease. For instance, KIAA1755 has been found to be associated with 
heart rate from exome chip meta analyses (29). We found a strong relationship between KIAA1755 and 
eicosapentaenoate (p<5e-14). The metabolite eicosapentaenoate is related to essential hypertension, which is the 
most common type of hypertension with no known cause (30)(31). From the identified metabolomic causal 
network based on Mendelian randomization principles, we found the metabolite eicosapentaenoate was among 4 
metabolites with high impact on arachidonic acid (3). It has also been validated clinically that arachidonic acid 
has the greatest positive impact on triglyceride levels, a risk factor of cardiovascular disease (26). To assess the 
effect of triglycerides on essential hypertensive patients, in a separate previous clinical study, 900 patients were 
examined and a link was found between increased plasma triglyceride levels with more fatal events in essential 
hypertensive patients (32). These relationships are depicted in Figure 7 and may provide some insights into the 
disease process. The gene KIAA1755 is a gene/protein of unknown function and findings here may reveal new 
avenues into the gene function and the understanding of the disease etiology. 
We found a significant influence of PDE4DIP on the metabolite dodecanedioate from a lipid 
pathway. Dodecanedioate supplementation in non-insulin-dependent diabetic patients (but not healthy controls) 
reduced glucose levels without altering insulin levels (33). Another interesting finding was that the gene MYO1A 
was found to have a strong impact on the metabolite heptanoate from a lipid pathway. This metabolite has been 
used as a treatment for Long-chain L-3 hydroxyacyl-CoA dehydrogenase deficiency, a condition in which the 
body is unable to break down certain fats (34).  
  
In Table 2, we showed significant associations between CLDN17 with increased levels of isoleucine (pvalue=2e-
12), and APOA1BP (pvalue=9e-13) with increased levels of leucine, in the AA population. The relationships were 
through heterozygous LoF variants, suggesting that haploinsufficiency of these genes results in an increase of the 
corresponding metabolites. Figure 8 illustrates that these two metabolites were highly connected in the causal 
network, meaning that their effects can spread across the metabolomic system by influencing multiple metabolites 
directly and indirectly. Note that all participants in AA population were from Jackson, Mississippi, in an attempt 
to control for environmental confounders, such as regional dietary variations that can influence the metabolome.   
 
Leucine and isoleucine are branched-chain essential amino acids. Studies have shown that higher levels of leucine 
or isoleucine are strongly related to insulin resistance, obesity, and higher risk of type 2 diabetes (35, 36). We 
found a strong association between the gene CLDN17 (Claudin-17) and isoleucine. This gene is a tight junction 
protein that facilitates anion-selective paracellular transportation and is predominantly expressed in proximal 
nephrons (37). There is evidence suggesting the electrogenic transport of amino acids including leucine and 
isoleucine by proximal tubules (38). APOA1BP is an apolipoprotein A-I (ApoA-I) binding protein, which is 
essential in maintaining cholesterol homeostasis and plays a role in cardiovascular disease (39). Low levels of 
ApoA-I and HDL cholesterol are linked to risk of cardiovascular events (40), whereas increases in several amino 
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acids, including leucine, are linked to low levels of HDL cholesterol and insulin resistance in patients with renal 
dysfunction(41).  
In the AA population, we found the metabolite gammaglutamylleucine from the peptide pathway was influenced 
by a LoF mutation in CYP2A6 (p-value=1e-11). The other related findings were relationships between CYP2A13 
and the metabolites pyroglutamine (p-value = 5.13e-07) and hydroxyphenyllactate (pvalue=1.81e-08). The LoF 
mutation in CYP2A13 revealed a pleiotropic action on two metabolites, pyroglutamine and hydroxyphenyllactate. 
CYP2A6 and CYP2A13 are both members of cytochrome P450 superfamily of enzymes, which are involved in 
many catalytic reactions and drug metabolism including nicotine metabolism. Genetic variants in these genes 
present a lower risk of developing tobacco-related lung cancer in multiethnic populations including African-
American smokers (42–44). An increased level of gammaglutamylleucine has been identified as an indicator of 
anti-obesogenic metabolism and the strongest risk-decreasing predictor of death (41). Additionally, the inhibition 
of CYP2A6- and CYP2A13-mediated metabolism of nicotine can increase the activity of gammaglutamylcysteine 
syntheses that results in the overproduction of pyroglutamate (40). It has been proposed that pyroglutamate has a 
xenobiotic detoxifying property (45). The second metabolite associated with CYP2A13 was hydroxyphenyllactate, 
which is a tyrosine metabolite, and the L-form of it has been reported to be highly elevated in the urine of patients 
with pheylketonuria and tyrosinemia. Taken together, using our approach, we identified two separate metabolites 
gammaglutamylleucine and pyroglutamine that had significant associations with LoF variants of two genes, 
CYP2A6 and CYP2A13, respectively from the same family of genes. Thus, these metabolites could be functionally 
related given their protective functions. Furthermore, our analysis method was able to uncover the potentially 
pleiotropic effects of the gene CYP2A13 on two different metabolites, pyroglutamine and hydroxyphenyllactate, 
that may act independently of each other. Nonetheless, further study is required to understand the biological 
functions of these genes on related metabolites and diseases. Identifying pleiotropic genes reveals important 
biological relationships among molecular components or clinical phenotypes and leads to understanding of 
complex biological mechanisms, disease pathogenesis and underlying co-morbidities (46)(47). This 
understanding may improve and speed drug development and furthermore, predict possible side effects (48)(49). 
Although systems approaches to molecular pathway identification will not replace mechanistic experiments, they 
are complementary and hypothesis-generating, especially in the era of large scale data to narrow the search space, 
identify targets for intervention, and define pathways that spread the effect of any intervention in the system. The 
integrated approach introduced here facilitates a mechanistic understanding through incorporating and modeling 
relationships of a large number of metabolites in genome analysis, improves genome pathway identification, and 
identifies genes with pleiotropic actions. The focus of the current study was on LoF variants. For future studies, 
we aim to extend the work to additional previously-identified associated genetic variants (7) and utilizing new 
clustering approaches (50)(51). 
Conclusions 
Metabolomic data function as an intermediate at the molecular level to illuminate mechanisms underlying a 
specific genetic variant, to identify biological pathways linking the genome to disease, and to discover valuable 
clinical biomarkers. By integrating results of the genome analysis with metabolomic relationships, and as a result, 
improving the focus on biological systems, including the identification of pleiotropic gene actions, we improved 
genome analysis and studied how naturally occurring genetic variants can affect metabolites.  
Methods 
Metabolomic and genomic data: The data was from the ARIC Study, which enrolled 15,792 middle-aged 
individuals (45 to 64 years) at baseline. For more details of the cohort characteristics see 
https://www2.cscc.unc.edu/aric/system/files/ CohortCharacteristics.pdf and Supplementary, table S1. Serum 
metabolomic and genomic data were available on 1376 individuals from the AA and EA populations in the study. 
The dbGAP accession number for ARIC study data is phs000668.v3.p1. A total of 602 metabolites were detected 
and semi-quantified by Metabolon Inc. (Durham, North Carolina). After excluding metabolites with at least 50% 
missing values across all samples, metabolites with unknown chemical structures, and metabolites (or any 
transformation of them) that did not follow a normal distribution, we focused on 122 named metabolites, 
Supplementary table S8. Details of metabolite assessments are provided in the next section and Supplementary, 
section Metabolite measurement. Replication samples were available; and we utilized them to identify and impute 
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the missing values with an optimal approach (52). Since covariates could have a profound effect on metabolites, 
we adjusted metabolites for age, gender, and body mass index, phase (two different time points that the metabolites 
were measured), and ten principal components (to adjust for population stratification) using a linear regression. 
In addition, we carried out the analysis for AA ad EA populations separately. LoF variants were defined as 
sequence changes caused by single nucleotide variants or small insertions and deletions. The exomes were 
sequenced on the individuals and 372 and 451 LoF variants were identified for AA and EA populations 
respectively (23). Variants were annotated using ANNOVAR (53) and dbNSFP v2.0 (23) according to the 
reference genome GRCh37 and National Center for Biotechnology Information Reference Sequence.  
After exome capture with VCRome 2.1 (NimbleGen, Inc., Madison, WI), sequencing was carried out using 
Illumina HiSeq instruments. Using Burrows-Wheeler aligner (54), sequences were aligned to Genome Reference 
Consortium Human Build 37. Allele calling and variant-call file construction were carried out with the Atlas2 
suite (Atlas-SNP and Atlas-Indel). Single-nucleotide variants (SNVs) were removed using the following criteria: 
SNVs with a SNP posterior probability less than 0.95, a total depth of coverage less than 6×, an allelic fraction of 
<0.1, fewer than three variant reads, 99% reads in a single direction and homozygous reference alleles with <6× 
coverage. More stringent filtering was applied on low-quality single-nucleotide substitutions with total depth less 
than 10; low-quality indels with the following differences: allelic fraction <0.2 for heterozygous variants and <0.8 
for homozygous variants, minimum total depth less than 60, and variant reads smaller than 30.  
All LoF varients in this study were confirmed to have a premature stop codon in a coding exon, disruption of an 
essential splice site, or an indel predicted to disrupt the downstream reading frame (23). 
Serum metabolomic and genomic data were available on an additional subset of individuals from the same 
population, 672 African-Americans, which were used to validate the findings in AA population.  
Metabolomic measurement 
Metabolic profiling was carried out on fasting serum samples from the baseline examination stored at -80C. 
Metabolites were measured using untargeted gas chromatography-mass spectrometry and liquid chromatography-
mass spectrometry (GC-MS and LC-MS-based quantification protocols by Metabolon, Inc., Durham, NC). 
Because the laboratory work for this study is expansive and spanned many days, a data normalization step was 
performed to correct for variation resulting from differences in instrument tuning from day to day. Metabolites 
were identified by comparison to library entries of purified standards or recurrent unknown entities. Several types 
of internal controls were analyzed in concert with the experimental samples. Tables S2 and S3 in supplementary 
describe these quality assurance and quality control samples and standards. Further QC consisted of four major 
components: the LIMS, the data extraction and peak-identification software, data processing tools for QC and 
compound identification. The proposed methods, although robust, assume normality of the metabolomics and risk 
factor data. Log transformation may not be the best transformation for all metabolites. Different transformations 
were assessed, such as square, root square, log etc., and different metabolites were transformed to a normal 
distribution using different transformations.   
Genome analysis: To select the genetic variants associated with metabolites, we applied  
1- Convex-Concave Rare variant Selection (CCRS). The CCRS approach (24) is a penalized model with some 
constraints on the design matrix and coefficient vector to provide parsimony of selected covariates,  similar to 
lasso penalization. Using this approach, we had a multivariable regression model which included all LOF variants 
in the model at a time. Therefore, in contrast to single variant tests, the CCRS approach is a multiple regression 
method that simultaneously selects the most promising genome variants and estimates their effects on metabolites 
of interest. Applying the CCRS not only increases the power of identification due to avoiding multiple comparison 
adjustments, it also takes into account local linkage disequilibrium and prevents overestimation.  
2- In addition to the CCRS, to identify mutations in the coding sequence with significant effect on metabolites, 
we sought association with the metabolites using a linear regression model for each variant at a time. For rare 
variants, we aggregated their effects by summing the number of LoF variants in each gene and then tested the 
association of this sum with metabolites by linear regression.  
3- We then focused on the variants that were commonly selected by the two steps above to reduce the false 
discovery rate.  
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Metabolomic causal networks: Metabolomic causal networks represent metabolites as nodes connected by 
directed edges indicating the relationships among metabolites. A missing link between two metabolites in the 
causal network means no relationship, and a link between two metabolites represents the relationship after 
conditioning on the effect of other metabolites in the analysis (conditional analysis). In a causal network, directions 
represent cause and effect relationships in observational studies identified based on Mendelian 
principles/instrumental variables, using variation in the system that is free of confounding (55)(56)(57). The G-
DAG (genome directed acyclic graph) algorithm (21)(25) with clinically validated novel findings (26) is based on 
the principle that the genome inherited variation is a causal factor of metabolomic changes and not the other way 
around. Some of applications of the G-DAG algorithm are (3)(20)(21)(25)(58). The G-DAG algorithm was 
employed to identify metabolomic causal networks, see below for the steps of the G-DAG algorithm. To enforce 
the assumptions of instrumental variable application and identify robust directions among metabolites, the G-
DAG algorithm has the following features (58):   
1. Extracting information from multiple genetic variants using principal component analysis to create strong 
instrumental variables; 
2. Independent instrumental variables due to application of principal component analysis; 
3. Multiple independent instrumental variables used for each metabolite, to make overall instrumental 
variables even stronger.  
 
For identification of the AA and EA metabolomic causal networks, in total 353 and 412 instrumental variables 
were utilized, respectively.  These instrumental variables that were generated from whole exome sequencing data 
represent the global genomic effects on metabolites despite an individual genetic variant effect. Figure S1 in 
Supplementary represents the outcomes of the G-DAG algorithm for EA and AA populations.  
To obtain the best fit for the networks, we employed structural Hamming distance (59), a well-established 
assessment for the quality of fit in networks, e.g. see (60)(61). The distance is a function of sample size, variables, 
and neighbors; a smaller distance indicates a better fit. We considered a set of tuning parameters including 0.0005, 
0,001, 0.005, 0.01, 0.05. For the setting with alpha 0.001 and 0.005 the average of the distance on 45 replications 
was minimum. Therefore, we carried out the analysis at statistical significance level 0.001.  
The G-DAG Algorithm  
The G-DAG algorithm (25) uses principal components (generated from genome variation) as strong instrumental 
variables to identify a stable network over the metabolites. Note that the primary aim was identification of a causal 
network over the set of variables of interest (here metabolites) and the genome information is used as a tool to aid 
in identifying directionality among the metabolites.  
First, we start by reducing the number of SNPs by considering the fact that some SNPs are nearly perfectly 
correlated (>0.80) with others, so that one SNP can thereby serve as a proxy for many others in the analysis. To 
determine a proxy, we use hierarchical clustering and a measure of linkage disequilibrium (62).  
Second, the genomic information was summarized using principal component analysis.  
Third, the set of principal components responsible for more than 90% of the variation was selected.  
Fourth, the tuning parameter in the G-DAG algorithm was set using the structural Hamming distance, which is a 
function of variables, sample size and neighboring.  
Fifth, in a constraint-based algorithm, the G-DAG identified a causal network over the principal components as 
instrumental variables and metabolites.   
Pleiotropy identification: The pleiotropic effect of an inherited gene can refer to a single nucleotide 
polymorphism (SNP), an entire gene, a large segment of the genome containing multiple genes (63), or regulatory 
motifs across the genome (64). We point out the definition of pleiotropy considered in this study as genes with 
more than one functionality, the ability of a gene to cause distinct phenotypic traits (65). The word “distinct” 
should not be interpreted as independent since some dependency can arise from shared environmental influences 
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and direct physiologic and biochemical relationships (66). Alternatively, in association studies, where one trait at 
a time is analyzed, a gene associated with more than one trait cannot be identified with pleiotropic action since 
this relationship might be due to association between the two traits and not different functionality of the gene. We 
assessed the pleiotropic action through identification of the genes with direct effect on more than one metabolite.  
When a study has a large number of traits, such as metabolites, illumination of underlying relationships provides 
an opportunity to improve the power of genome analysis, and consequently identification of pleiotropic gene 
actions. Using causal networks established in principles of Mendelian randomization and application of structural 
equation modeling, we identified pleiotropic actions by removing findings that are due to metabolomic 
relationships and not the gene’s direct effect on metabolites. 
Structural equation modeling: Here, structural equations were used to model genetic variants with pleiotropic 
effects based on the relationships of genetic variants and metabolites. In the general form, with M representing 
metabolites and G representing genetic variants, the structural equations are 
𝑀𝑖|𝐴𝑀(𝐾𝑅) = ∑ 𝜆𝑖𝑗𝑀𝑗 + 𝑈𝑖
𝑙
𝑗=ℎ+1
 
𝑈𝑖|𝐴𝑀(𝐾𝑅) = ∑ 𝛾𝑖𝑚𝐺𝑚 + 𝑒
ℎ
𝑚=1
 
where m = 1,…, h ; j = h+1,…, l ; i = l+1; and 𝜆𝑖𝑗 ≠ 0 is equivalent with (j ⟶ i) and  𝛾𝑖𝑚 ≠ 0 is equivalent with 
(m ⟶ 𝑖). The notation 𝐴𝑀(𝐾𝑅) is called casual parameter (55). It stands for Assignment Mechanism given the 
Knowledge about Response (67). To assure that the assumptions of structural equation modeling were met, we 
first identified the metabolomic causal networks. The causal networks are illustration of Assignment Mechanisms 
behind observations (67) (68) which can be illuminated by gathering any Knowledge about Response variables. 
The reason for conditioning the equations above on the causal parameter is to show that the equations are written 
based on an identified causal network that meet the required assumption. Note that in a metabolomic causal 
network, each metabolite is a response variable and the causal network represents metabolites that were involved 
in assigning value to each response variable (a metabolite). For applications of structural equation modeling see 
(27)(69). 
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Figure Legends 
Figure 1. The steps to conduct gene-metabolite investigation. Abbreviation: SEM: structural equation 
modeling; CCRS: convex-concave rare variant selection; G-DAG: genome directed acyclic graph. Details 
of the CCRS method (for the genome analysis) and the steps of the G-DAG algorithm (for constructing 
metabolomics causal networks) are described in the methods section.  
 
Figure 2. GPR97-metabolite pathway. The red cross represents the pathway that is not significant after 
modeling the correlated metabolites using structural equation modeling. In the figure, glycocholenate 
stands for glycocholenate-sulfate.  
 
Figure 3. BNIPL-metabolite pathway. The red cross represents that the pathway was not significant after 
modeling the relationship between the metabolites octanoylcarnitine and decanoylcarnitine.   
 
Figure 4. The module including metabolites related to gut metabolism. Urea and glutarylcarnitine are 
neighbors of the module. Metabolites influenced by LoF mutations in AA population are depicted in larger 
scale.  
Figure 5. Hormone related metabolites as a module and pyroglutamine as a neighbor of the module. The 
metabolites influenced by LoF mutations in AA population are depicted in larger scale. Abbreviation: 
aS1/2 stands for andersten-3-beta-17-betadiol-disulfate1/2. The capital S at the end of glycocholenateS, 
pregnendioldiS, hydroxypregnenolonediS, and pregnsteroidmonoS stands for sulfate.  
 
Figure 6. Left panel: MAF<20% for LoF mutations. Right Panel: MAF% for LoF mutations identified 
with significant impact on metabolites. The x-axes indicate the alternative allele, and the y-axes indicate 
the MAF%.  
Figure 7: A pathway from the genome to metabolic disorder and cardiovascular disease through 
metabolomics and the risk factors. Yellow represents metabolites. Red indicates risk factors of 
cardiovascular disease and components of metabolic disorder. Abbreviations: TG: Triglycerides, EPA: 
Eicosapentaenoate, EH: Essential Hypertension, Docosapentaenoyl-G: Docosapentaenoyl-
Glycerophosphocholine 
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Figure 8. The impact of leucine and isoleucine on metabolomics. Leucine and isoleucine influence 
multiple neighboring metabolites, broadly influencing the system.  
 
Supplementary files  
1. Figure S1. European-American metabolomic causal network using the G-DAG algorithm.  
2. Table S1. Characteristics of ARIC Cohort  
3. Metabolite assessment and Tables S2 and S3 for QC. 
4. Tables S4 and S5. LoF-metabolite relationships using the CCRS approach for EA and AA 
populations respectively.  
5. Tables S6 and S7. LoF-metabolite relationships using the single variant test for EA and AA 
populations respectively.  
6. Table S8. List of 122 named metabolites measured in ARIC study 
Table 1. EA (European-American) population, LoF-metabolite relationships at p-value 4e-07 or smaller. Effect sizes 
measured in standard deviation units to facilitate comparison. The last column “Human phenotypes related to metabolites” 
was obtained through Human Metabolome database, http://www.hmdb.ca/. 
Gene SNP MAF Metabolite Path- 
way 
Effect  
Size 
(Std. 
Error) 
p- 
value 
Human phenotypes related to 
metabolites  
TPTE X21:10907041:C:A 8 
O-sulfo-L-tyrosine - 1.75 
(0.34) 
2e-07  
myoinositol  Lipid 2.23 
(0.35) 
2e-10 Schizophrenia 
MYO1A X12:57441459:G:A 9 
heptanoate 
 
Lipid 
 
1.95 
(0.33) 
4e-09 Cardiac disease 
glycerol Lipid 
  
1.70 
(0.33) 
3e-07 Schizophrenia, Diabetes mellitus 
type 2 
GZMM X19:549171:C:T 
 
4 octanoylcarnitine   
 
Lipid 
  
1.46 
(0.26) 
4e-08 Medium-chain acyl-CoA 
dehydrogenase deficiency 
PLAC4 
 
X21:42551432:T:A 9 androsten-3-beta-17 
beta-diol-disulfate1 
Lipid 
 
1.95 
(0.33) 
4e-09 NA 
 
LRTOMT 
 
X11:71807767:A:C 10 betaine  0.67 
(0.23) 
7e-09 Chronic renal failure and hemodialysis, 
Schizophrenia  
PDE4DIP X1:145074975:G:A 17 dodecanedioate Lipid 1.84 
(0.24) 
1e-14 Diabetes mellitus type 2 (34)  
OBSCN X1.228469903.A.T 8 serine Amino 
acid 
1.89 
(0.34) 
7e-08 Schizophrenia and epilepsy, Leukemia, 
Heart failure 
THSD7B X2:138030234:C:T 19 glycylvaline Peptide 1.61 
(0.23) 
1e-12 NA 
C5orf45 X5:179280392:G:A 8 cis-4-decenoylcarnitine Lipid 3.10 
(0.34) 
2e-16 Celiac disease, Very long chain acyl-
Coa dehydrogenase deficiency   
 
 
DSE X6.116600895.G.A 10 pregn steroid monosulfate Lipid 1.65 
(0.31) 
1e-07 Schizophrenia 
 EGFL8 X6:32134395:C:G 8 myristoleate Lipid 2.51 
(0.35) 
8e-13 NA 
GPNMB X7:23313823:G:T 12 lactate Amino  
acid 
1.80 
(0.28) 
3e-10 Hepatobiliary, Psychiatric, 
Mitochondrial dysfunction, 
Metabolism and nutrition disorders 
C10orf53 X10:50901917:C:A 8 hydroxybutyrate Amino  
acid 
1.78 
(0.35) 
4e-07 Schizophrenia, Pyruvate 
dehydrogenase deficiency 
 
 
 
SERPINA10 X14:94754643:C:T 14 prohydroxyproline  1.45 
(0.26) 
4e-08 NA 
LTK X15:41796352:C:A 8 glycocholenatesulfate Lipid 2.04 
(0.35) 
6e-09 NA 
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CCDC154 X16:1484536:C:T 14 glycerol- 
phosphorylcholine 
Lipid 1.41 
(0.26) 
1e-07 Multi-infarct dementia  
RHBDL1 X16:726189:C:T 14 phosphate Lipid 1.75 
(0.26) 
4e-11 NA 
ZNF211 X19:58153465:T:A 12 myristoleate Lipid 1.73 
(0.28) 
1e-09 NA 
 
 
 
Table 2. AA (African-American/non-white) population LoF-metabolite relationships at p-value 1e-6 or smaller. Effect sizes 
measured in standard deviation units to facilitate comparison. The column, “Human phenotypes related to metabolites” was 
obtained through Human Metabolome database, http://www.hmdb.ca/. LCAC: long-chain acylcarnitine. The last column 
represents the p-value in the replication analysis. Genes with asterisk are replicated.  
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Gene SNP MAF Metabolite Path- 
way 
Effect  
Size 
(Std.Erro
r) 
p- 
  value 
Metabolite related human phenotypes Rep- 
lication 
p-value 
GPR97 X16:57707232:G:C 4 
glycocholenat
e-sulfate 
Lipid 1.09 
(2.34) 
3e-11 _  
NA 
 oleate Lipid 1.79 
(0.35)     
 
4e-07 LCAC accumulation, Inflammation, 
Schizophrenia, Gestational diabetes 
 
 
GGN X19:38875072:G:A 8 
androsten-3-
beta-17-beta- 
diol-disulfate 1 
Lipid 1.68 
(0.27) 
1e-09 -  
 
NA 
xanthine Nucleotide 1.63 
(0.28) 
 
4e-09 Nervous system disorders, Renal 
failure 
CYP2A13 X19:41594954:C:T 6 
pyroglutamin
e 
Amino  
acid 
1.67 
(0.33) 
5e-07 Nervous system, and Metabolism & 
nutrition disorders 
 
NA 
 
hydroxypheny
llactate 
Amino  
acid 
1.87 
(0.33) 
2e-08 Supradiaphragmatic malignancy. 
Liver dysfunction  
CLDN17 X21:31538461:G:A 8 
isoleucine Amino  
acid 
1.96 
(0.29) 
8e-12 Heart failure, Leukemia, Maple syrup 
urine disease 
 
NA 
glycerol Lipid 1.72 
(0.29) 
2e-09 Schizophrenia, Diabetes mellitus 
type 2  
CYP2A6 X19:41351363:T:A 6 
gamma- 
glutamylleuci
ne  
Peptide 1.92 
(0.28) 
1e-11 NA  
 
NA 
Gamma- 
glutamylthreo
nine     
Peptide 1.27 
(0.30) 
1e-10 - 
ZSWIM1 X20:44511257:G:A 7 Phenylacetyl- 
glutamine 
Amino  
acid 
2.75 
(0.35) 
4e-15 NA NA 
CRYBB3 X22:25599863:G:T 3 trans-4-
hydroxyprolin
e 
Amino  
acid 
2.19 
(0.37) 
6e-09 Renal disorder NA 
STPG1 X1:24727815:G:T 3 gamma-
glutamyl-
glutamate 
Peptide 2.49 
(0.35) 
1e-12 NA NA 
CLSPN X1:36208741:C:T 7 urea Amino  
acid 
2.13 
(0.28) 
1e-13 Infection NA 
CLEC4C X12:7899913:C:A 4 nonadecanoat
e 
Lipid 2.36 
(0.37) 
4e-10 NA NA 
BNIPL X1:151016171:G:A 3 decanoylcarni
tine 
 2.17 
(0.35) 
7e-10 Medium-chain acyl-CoA 
dehydrogenase deficiency  
NA 
MAP10 X1:232942469:G:A 6 oleate Lipid 2.07 
(0.35) 
4e-09 LCAC accumulation, Inflammation, 
Schizophrenia, Gestational diabetes 
NA 
OR11G2 X14:20666175:C:A 22 gamma- 
glutamylleuci
ne 
Peptide 1.11 
(0.18) 
9e-10 NA 0.03 
FAM151A X1:55075006:G:A 6 pregnendiol-
disulfate 
Lipid 2.59 
(0.35) 
2e-13 Schizophrenia 
 
NA 
APOA1BP X1:156563265:C:T 4 leucine Amino  
acid 
2.51 
(0.35) 
9e-13 Heart failure, Leukemia, Maple syrup 
urine disease 
NA 
KIAA1755 X20:36869005:G:A 8 eicosapentaen
oate 
Lipid 2.08 
(0.27)  
5e-14 Essential hypertension NA 
ELSPBP1 X19:48523114:G:A 4 erythritol Xenobioti
cs 
2.52 
(0.38) 
2e-11 Pentose phosphate pathway 
abnormalities 
NA 
COASY X17:40717487:A:G 8 gamma- 
glutamylgluta
mate 
Peptide 1.76 
(0.29) 
4e-09 NA NA 
CD300C X17:72540958:G:A 4 docosahexaen
oylglycero-
phosphoethan
olamine1 
Lysolipid 2.11 
(0.30) 
2e-12  
 
 
NA 
C16orf55 X16:89724661:G:T 11 androsten-3-
beta-17-beta-
diol-disulfate 
2 
Lipid 1.98 
(0.24) 
2e-16 NA 
 
NA 
17 
 
 
 
 
C15orf32 X15:93015466:A:T 17 glycerol-3-
phosphate 
Lipid 1.11 
(0.19) 
4e-09 NA 0.9 
LTK X15:41799325:G:A 18 urea Amino  
acid 
1.14 
(0.19) 
6e-09 Infection  0.6 
AVEN X15:34159987:G:A 4 urea Amino  
acid 
1.71 
(0.30) 
2e-08 Infection NA 
UPK2 X11:118827917:G:
A 
7 glycerol Lipid 1.89 
(0.30) 
3e-10 Schizophrenia, Diabetes mellitus 
type2 
 
 
NA 
SLC25A27 X6:46623768:G:A 21 O-sulfo L-
tyrosine 
- 1.24 
(0.20) 
1e-09 NA NA 
DCLK3 X3:36756821:A:C 10 phenylacetylg
lutamine 
Amino 
acid 
1.62 
(0.28) 
4e-09 NA NA 
TMPRSS3 X21:43792873:A:G 11 phenylacetylg
lutamine 
Amino 
acid 
2.04 
(0.25) 
2e-16 NA NA 
GUCA1C X3:108672558:C:A 6 glutarylcarniti
ne 
Amino  
acid 
2.32 
(0.35) 
4e-11 NA NA 
NWD1* X19:16908698:G:A 22 carboxy4meth
yl5propyl2fur
anpropanoate 
Lipid 0.97 
(0.10) 
1e-06 
 
Psychiatric, kidney, cardiovascular 
and gastrointestinal disease, seizure  
 
1e-8 
POLR1E* X9:37495945:C:A 21 glycerol3phos
phate 
Lipid 1.50 
(0.23) 
2e-10 
 
Multi-infarct dementia 3e-20 
P2RX7* X12:121570899:G:
T 
8 tyrosine Amino  
acid 
1.59 
(0.32) 
7e-07 Leukemia, Hypothyroidism, 
Myocardial infection, Schizophrenia, 
Epilepsy 
1e-7 
CAPN11* X6:44147355:G:A        14 aminobutyrate          Amino  
acid 
1.18 
(0.23) 
7e-07 Metabolism, hepatic disorder, 
Epilepsy, Aciduria, Febrile seizures,  
1e-7 
OR11H4* X14:20711121:T:A    22 catecholsulfat
e       
Xenobioti
cs 
 
1.24 
(0.19) 
2e-10 NA 1e-7 
 
C6orf25* 
 
X6:31692558:C:T 
 
10 
leucine 
Amino  
acid 
1.85 
(0.31) 
7e-09  
 
Heart failure, Leukemia, Maple syrup 
urine disease,  Schizophrenia, 
Epilepsy 
8e-13 
isoleucine 1.79 
(0.27) 
1e-10 5e-14 
valine 1.72 
(0.20) 
3e-09 2e-17 
